Limertinib (diTFA)

Limertinib (ASK120067) diTFA is a potent and orally active inhibitor of EGFRT790M (IC50: 0.3 nM) with selectivity over EGFRWT (IC50: 6.0 nM) . limertinib diTFA is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC) [1].

Product Specifications

Product Name Alternative

ASK120067 (diTFA)

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/limertinib-ditfa.html

Concentration

10mM

Purity

98.96

Solubility

DMSO : 175 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(NC2=NC=C(C(NC3=CC4=C(C=CC=C4)C=C3)=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)C=C.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

Molecular Formula

C33H34ClF6N7O6

Molecular Weight

774.11

References & Citations

[1]Tao Zhang, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19 (1) :90.